Kornimate/medical-research-clean huggingface dataset:
application of contrast enhance ultrasound to evaluate hemodynamics change in mca with moderate to severe stenosis

Conditions: Stenosis

Summary: objective: to monitor and evaluate the change of intracranial hemodynamics and mca stenosis after 24-week atorvastatin treatment using ceus, cta and dsa. study design: total 30 patients (60 arteries) will be enrolled in this study, who had mca infarction within 6 months prior to screening, and has not received any statins treatment before stroke. eligible patient will receive atorvastatin 40mg treatment for 24 weeks. hemodynamics changes and mca stenosis will be evaluated using ceus at baseline, 3-month,and 6-month. mca stenosis, bloodstream velocity, as well as clinical symptoms will be assessed at each visit and compared to baseline.

the cerebral infarction resulted from medially and heavily narrow mca is determined by the three-type screen method .for the first screen cerebral infarction patients of mca area who has the stroke or tia history in 6 months are determined by the clinic stroke measure table,transstadial doppler ultrasonography (tcd) carotid ultrasonography and skull ct. for the second the mac area infarction and vessel narrow are determined by the skull magnetic resonance (mri) and magnetic resonance vessel imaging (mra) and the mca trend bloodstream dynamics feature and narrow extent are observed by the strengthened ultrasonography (cevs) for the third, the mca narrow extent is measured by the dsa test which is currently regarded as a gold standard and /or by the cta .the atorvastatin 20mg treatment is given to the patients who all use the antiplatelet medicine the clinic symptom improvement mca narrow extent and bloodstream velocity are dynamically observed visited and analysed respectively at the basic line 3 and 6 months after treatment

Eligibility criteria:
inclusion criteria: * patients who had mca infarction of unilateral with moderate to severe stenosis within 6 months prior to screening, and has not received any statins treatment before stroke. exclusion criteria: * with side of extracranial carotid artery 70-100% severe narrow or block * vertebrobasilar artery lesions caused by cerebral infarction * have rheumatic heart disease, the atrial fibrillation of heart disease, those who cerebral hemorrhage patients * serious liver and kidney function is not complete patients.

Keywords: atherosclerosis stenosis statin therapy signs and symptoms circulatory; change
lynparza breast cancer clinical experience investigation

Conditions: Breast Cancer

Summary: to characterise the development of adrs of bone marrow depression in patients under actual post-marketing use

to characterise the development of adverse drug reactions (adrs) of bone marrow depression in patients with unresectable or recurrent brca mutated her2 negative breast cancer who have previously received anticancer chemotherapy under actual post-marketing use.

Eligibility criteria:
inclusion criteria: * unresectable or recurrent brca mutated her2 negative breast cancer with prior anticancer chemotherapy exclusion criteria: * the patients who are not started on lymparza for the first time
identification of factors associated with treatment response in patients with polycythemia vera, essential thrombocythemia, and pre-myelofibrosis.

Conditions: Myeloproliferative Neoplasm

Summary: first-line treatment for patients with polycythemia vera, essential thrombocythemia, and pre-myelofibrosis is based on hydroxyurea or pegylated interferon. the objective of treatment is to prevent thrombotic complications and leukemic transformation. despite overall good response rates, some patients do not respond to treatment and others lose their response over time. both situations are associated with worse survival and there are to date no clear predictive factors for response although the existence of additional mutations seems unfavorable. in this exploratory study, we hypothesize that biological factors at diagnosis are associated with hematological response at 12 months. we will more specifically study the association between mutational profile, assessed by next-generation sequencing, and cytokine profile with hematological response. this study will help in identifying patients who will not respond to hydroxyurea or pegylated interferon and give the opportunity to try other treatments upfront, in the perspective of precision medicine. on the basic science side, this study will help in understanding the molecular and immunological factors involved in resistance to treatment.


Eligibility criteria:
inclusion criteria: * adults with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis. * indication for first-line treatment with hydroxyurea or pegylated interferon. * consent to participate. * affiliated to social security. exclusion criteria: * previous treatment. * other on-going malignancy, including overt myelofibrosis. * other treatment such as phlebotomy solely, ruxolitinib, anagrelide, or pipobroman.
comparison of postoperative pain score between perioperative intravenous ketamine and placebo in patients undergoing unilateral total knee arthroplasty under general anesthesia

Conditions: Knee Osteoarthritis

Summary: the goal of this clinical trial is to compare postoperative pain score between perioperative intravenous ketamine and placebo in patients undergoing unilateral total knee arthroplasty under general anesthesia. the main question\[s\] it aims to answer are: * can perioperative intravenous ketamine reduce postoperative pain score during rest and movement at 0, 2, 4, 8, 12, 18, 24 hours better than no administration of ketamine in patients undergoing unilateral total knee arthroplasty under general anesthesia? * can perioperative intravenous ketamine reduce morphine consumption in postoperative 24 hours, length of hospital stay, first time to receive opioid and side effect or complication from ketamine and opioid better than no administration of ketamine in patients undergoing unilateral total knee arthroplasty under general anesthesia? participants will receive intravenous ketamine intraoperative tka and comparison group will receive placebo that is normal saline. researchers will compare perioperative intravenous ketamine and placebo to see postoperative pain score, morphine consumption in postoperative 24 hours, length of hospital stay, first time to receive opioid and side effect or complication from ketamine and opioid.


Eligibility criteria:
inclusion criteria: 1. a patient undergo unilateral total knee arthroplasty under general anesthesia at chomthong hospital chiang mai during 2024 to december 2025 2. age is more than 18 years old 3. asa (american society of anesthesiologist) status are i,i,iii 4. a patient can cooperate in research exclusion criteria: * patients allergic to local anesthetic agent * patient who has contraindication to use ketamine * patients has coagulopathy. * injection site is infected. * patients with chronic pain received painkillers for more than 3 months. * the patient has a history of opioid use. * the patient has a history of alcohol dependence. * patients allergic to fentanyl or morphine. * patient who has unstable cardiovascular disease * patient who has increase intracranial pressure and high ocular pressure * pregnancy * the patient who has communication problems cannot describe the level of pain * the patient refused to participate in the study.

Keywords: ketamine total knee arthroplasty general anesthesia total knee arthropathy
microsurgery using a bioceramic root end filling material

Conditions: Bone Resorption; Symptoms

Summary: endodontic failures are not uncommonly encountered despite improvements in routine root canal therapy. endodontic microsurgery is one way to manage such failure. the placement of a retrograde filling material is considered the most important prognostic factor in endodontic microsurgery. the aim of this study was to investigate the clinical and radiographic outcome of a fast set bioceramic root end filling material in human teeth.

patients who were referred to the endodontic postgraduate clinics in the period between january 2017 till august 2017 were assessed for inclusion in the study according to preset criteria. endodontic microsurgery was performed following modern techniques including magnification, root resection with minimal angle, ultrasonic root end preparation and placement of a fast set bioceramic putty as retrograde filling material. the case was subsequently evaluated clinically and radiographically at 3, 6 and 12 months. and will be followed subsequently at 2 years and 4 years post treatment.

Eligibility criteria:
inclusion criteria: 1. medically fit patient 2. tooth has adequate coronal seala nd judged restorable 3. previously root filled tooth with persistent periapical lesion 4. previously retreated tooth with persistent symptoms 5.previously tretaed tooth with inaccessable canal for retreatment 6. combined nonsurgical and surgical approach for teeth with large periapical lesions exclusion criteria: * medically compromised patients * nonrestorable teeth cracked roots

Keywords: rarifaction root end filling bioceramic outcome
effect of cognitive behavioral therapy in ocd highlighted by neuropsychological tests and mri: pathophysiology and treatment outcome predictors

Conditions: Obsessive-Compulsive Disorder

Summary: ocd patients are assessed before and after treatment using diagnostic tools, rating scales neuropsychological assessment and functional and structural mr-scans.


Eligibility criteria:
inclusion criteria: 1. steady state medication 3 months prior to the study exclusion criteria: 1. history of head trauma or other organic brain disease 2. pregnancy. 3. pacemaker or other ferromagnetic materials in the body. 4. comorbid psychiatric illnesses assessed using scan- interview (30) other than moderate depression (ham-d\<17) or anxiety disorders. 5. antipsychotics

Keywords: psychological tests magnetic resonance imaging cognitive therapy
post-marketing surveillance of the tanreqing injection: a real world study

Conditions: Adverse Drug Reaction; Drug Allergy

Summary: tanreqing injection is widely used in respiratory disease with chinese medicine syndrome of retention of phlegm and heat in fei. this study record clinical use of tanreqing injection in the real world, observe the adverse drug reactions/ adverse drug events during treatment, and figure out why tanreqing induced severe allergic reaction happens.

as a compound traditional chinese medicine, tanreqing injection was approved by china food and drug administration(cfda) in 2003, and widely used respiratory disease, such as biofilm related upper respiratory infections, pneumonia and bronchitis. during its 11 years marketing in china, there was hardly any serious adverse drug reactions except for a few cases reported as severe allergic reaction. in this study, clinical pharmacists in selected hospitals will not only record the clinical use and the adverse drug reactions/ adverse drug events of this injection, but also try to figure out why drug-induced severe allergic reaction happens through a nested case-control study. this real world study for tanreqing injection with 30400 patients will be conducted from january.2014 to june.2016.

Eligibility criteria:
inclusion criteria: * patients who use the tanreqing injection in selected hospitals in china, including inpatient and outpatient. * outpatients will be only in some hospitals which can get the patients' complete information. exclusion criteria: * patients who are less than 24 months.

Keywords: traditional chinese medicine injection
exercise reset for concussion in a military environment

Conditions: Brain Concussion

Summary: our primary objective is to show that early, personalized aerobic exercise treatment safely improves concussion recovery, speeds rtd, and reduces persistent symptoms in csm. our secondary objectives include demonstrating the clinical utility of our march-in-place test and determining fundamental mechanisms for the effect of exercise rehabilitation on concussion recovery.

aim 1: determine whether early sub-threshold aerobic exercise (i.e., light limited duty added to the current department of defense progressive return to activity \[dod pra\]) protocol speeds return to duty (rtd), improves clinical recovery, and protects against risk of persistent post-concussive symptoms(ppcs). hyp 1.1: aerobic exercise+dod pra early after injury speeds rtd and improves clinical recovery in csm compared to the dod pra protocol alone. hyp 1.2: early aerobic exercise+dod pra protects against risk of ppcs in concussed service members (csm) at 1 and at 3 months post-injury versus the dod pra protocol alone. aim 2: determine whether a march-in-place test informs clinical decision-making and contributes to rtd decisions. hyp 2.1: the degree of early exercise intolerance on the buffalo concussion march test will correlate with the development of ppcs and inform clinician decision making on rtd. aim 3: determine how aerobic exercise improves concussion recovery. hyp 3.1: aerobic exercise improves abnormal autonomic nervous system regulation in csm. hyp 3.2: aerobic exercise reverses changes in salivary brain-derived neurotrophic factor (bdnf), bdnf-related micro rnas, and inflammatory-related mirnas seen in csm. hyp 3.3: aerobic exercise improves mental health (i.e., anxiety/depressive symptoms, sleep, resilience, self-efficacy, morale) in csm.

Eligibility criteria:
inclusion criteria: * aged 18-40 years, * within 9 days of injury * diagnosed with concussion by an experienced clinician using standard international criteria exclusion criteria: * moderate or severe tbi as indicated by a gcs score \<13, lesion on ct/mri, and/or focal neurologic sign consistent with intracerebral lesion * injury involving loss of consciousness for \>30 minutes or post-traumatic amnesia \>24 hours * inability to exercise because of lower-extremity orthopedic injury, clinically significant vestibular or visual dysfunction, or increased cardiac risk * pre-existing conditions that prevent participation in active testing and/or rehabilitation * history of more than 3 diagnosed concussions * currently on medications that affect autonomic function, such as adhd medication or mood stabilizers * active substance abuse/dependence * unwillingness to perform intervention * limited english proficiency.

Keywords: aerobic exercise military service member* concussion management
study of immune response in adults and elderly subjects vaccinated with inactivated influenza vaccines

Conditions: Influenza; Orthomyxovirus Infections; Myxovirus Infection

Summary: to further characterize the immune responses induced after an influenza vaccination performed either via the id or the im routes in two clearly distinct populations. objectives: * to describe the immune response per age group and vaccine group after vaccination. * to describe the safety of the vaccines per age group and per vaccine group after vaccination.


Eligibility criteria:
inclusion criteria : * aged 18 to 40 years (adults) or 60 to 85 years (elderly) * provision of a signed informed consent * able to attend all scheduled visits and comply with all trial procedures * for a woman of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to vaccination, until 4 weeks after vaccination * entitlement to national social security. exclusion criteria : * for a woman of child-bearing potential, known pregnancy or positive urine pregnancy test * breast-feeding woman * participation in another clinical trial investigating a vaccine, drug, medical device or a medical procedure in the 4 weeks preceding the trial vaccination * planned participation in another clinical trial during the present trial period * known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy * known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances * chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator * current alcohol abuse or drug addiction, which may interfere with the subject's ability to comply with trial procedures * receipt of blood or blood-derived products in the past 3 months, which might interfere with the assessment of immune response * receipt of any vaccine in the 4 weeks preceding the trial vaccination * planned receipt of any vaccine in the 4 weeks following the trial vaccination * known human immunodeficiency virus, hepatitis b or hepatitis c seropositivity * previous vaccination against influenza in the previous 6 months * thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding the inclusion contraindicating im vaccination * subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent * febrile illness (oral temperature \>=37.5°c) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment

Keywords: influenza orthomyxoviruses myxovirus infection inactivated split-virion influenza vaccine adults elderly
urethral length measurement in women undergoing suburethral sling operative procedure

Conditions: Stress Urinary Incontinence

Summary: this is a prospective, non-randomized, observational, multicenter study in which urethral length is measured in women with surgically-correctable stress urinary incontinence who undergo a suburethral sling operative procedure.

this is a prospective, non-randomized, observational, multicenter study in which urethral length is measured in women with surgically-correctable stress urinary incontinence who undergo a suburethral sling operative procedure. data will be collected from preoperative urogynecological testing and medical histories. the urethral length will be measured intraoperatively using scaled catheters. outcome data, including the development of postoperative complications, will be collected at several time intervals.

Eligibility criteria:
inclusion criteria: 1. patient has objective, demonstrable signs of stress urinary incontinence (sui), including patients with intrinsic sphincter deficiency (isd). objective testing includes: standing stress test, urodynamics evaluation or pad test. 2. patient is age 18 or older. 3. patient agrees to participate in the study, including completion of all study-related procedures and evaluations, and documents this agreement by signing the institutional review board/ethics committee-approved informed consent form. 4. patient is able to fill in all questionnaires (based on judgment of investigator) exclusion criteria: 1. patient has an associated or suspected neurological disease. 2. patient has an active lesion or present injury to perineum or urethra. 3. patient has a urethral obstruction. 4. patient has significant pelvic organ prolapse (grade iii/iv) requiring surgical treatment. 5. patient has current urinary tract infection.

Keywords: stress urinary incontinence suburethral sling
study evaluating enbrel in adults with active rheumatoid arthritis in luxemburg

Conditions: Rheumatoid Arthritis

Summary: the purpose of the study is to determine the long term safety of enbrel in adults with active rheumatoid arthritis in luxemburg. this is a post-marketing surveillance study in rheumatology practice patients. all patients initiated with enbrel will be observed from the start of the study in feb 2003 for a period of at least 5 years.


Eligibility criteria:
inclusion criteria: * have moderate to severe active rheumatoid arthritis * be aged of 17 years or more * have inadequate response to dmards * give written informed consent * physician decides to prescribe enbrel exclusion criteria: n/a

Keywords: rheumatoid arthritis
mri assessment of pulmonary edema in acute heart failure

Conditions: Acute Heart Failure; Pulmonary Edema With Heart Failure

Summary: researchers are testing a more accurate way to measure how much fluid is in the lungs (also called pulmonary edema, or "increased lung water") in people with heart failure (hf) using mri (magnetic resonance imaging). there is little known about the exact level of lung water in patients with ahf or how these levels change from the time of hospital admission to discharge. the purpose of this research study is to measure the lung water in patients hospitalized for hf, to determine the change in lung water over the course of hospitalization and treatment, and to find out if lung water levels can predict if patients are higher or lower risk for returning to the hospital or dying from heart failure.

heart failure is a condition where the heart is unable to pump enough blood to meet the body's needs and acute heart failure is a sudden worsening of this condition. it is associated with many symptoms but most commonly includes shortness of breath due to pulmonary edema (or increased "lung water"). a physical exam and chest x-ray are commonly used to diagnose ahf and estimate the amount of increased lung water in patients with ahf. this study will use images from mri (magnetic resonance imaging) scans to obtain a more accurate measurement of the increased lung water in ahf patients. lung water will be measured via mri at hospital admission and discharge to find out the change in lung water over the course of hospitalization and treatment. the investigators will collect nt-probnp and perform a chest x-ray upon hospital admission and again upon discharge, if not already done as part of usual care. the investigators will follow medical records for up to 5 years after hospitalization to see if the accurate lung water measurements obtained in hospital can predict long term outcomes. this is a multi-centre project and a total of 300 patients will be recruited to participate.

Eligibility criteria:
inclusion criteria: * 18 years of age or older and willing/able to provide informed consent * patients being treated for acute heart failure (including those patients with both reduced and preserved ejection fraction) * patients receiving medical therapy for pulmonary edema by current standard of care (including oral or iv diuretics) * patients identified within 48 hours of initiation of medical therapy for pulmonary edema, defined as the time of first diuretic (iv or po) or escalation of existing diuretic therapy administered within the ed or hospital exclusion criteria: * contraindication to mri * patient too critically ill/unstable as per the clinical care team for transport to mri scanner within the required scanning window * moderate to severe dementia